Neumora Therapeutics, INC Form 4 insider transactions

Director Maykin Ho reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Director David Piacquad reported the acquisition of 20,100 shares of common stock and options to purchase 28,571 shares of common stock in Neumora Therapeutics.

Director Alaa Halawa reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Director Matthew K. Fust reports acquisition of Neumora Therapeutics stock and options, signaling potential insider confidence.

Kristina Burow, a director and 10% owner of Neumora Therapeutics, Inc., filed a Form 4 detailing changes in her beneficial ownership, including the acquisition of restricted stock units and stock options.

Daljit Singh Aurora, Chief Strategy Officer of Neumora Therapeutics, transferred 114,703 shares of common stock to the Aurora Family Trust on April 22, 2024.